Navigation Links
Aurigene to Present its CDK7, Dual PD-1/VISTA and IRAK4 Inhibitor Programs at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 5-9, Boston, MA)

BOSTON, November 3, 2015 /PRNewswire/ --

Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program, which is currently in Lead Optimization.


Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the AACR-NCI-EORTC International Conference.

Aurigene and Curis will present data on:

(A) First-in-class orally available PD-L1/VISTA antagonists for cancer therapy

(B) interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor  

Additional information on the presentations can be found below and abstracts can be accessed at  

Poster Presentations  

First-in-class orally available immune checkpoint antagonists: PD-L1/VISTA  

Title: First-in-class orally available immune checkpoint antagonists for cancer therapy  

Session ID:               Poster Session A

Session Title:            Immune Modulators

Session Date and Time:     Friday Nov 6, 2015 12:15 PM - 3:15 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: A96

Selective CDK7 Covalent Inhibitors  

Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors Session Category: Experimental and Molecular Therapeutics  

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                  Exhibit Hall C-D

Permanent Abstract Number: C190

Novel, selective IRAK4 Inhibitors for Oncology  

Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models   

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: C191

About Aurigene:  

Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene's website at

Media Contact:
Rajshree KT
Director Corporate Development & Strategy
+91-40-4465 7777 

SOURCE Aurigene Discovery
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SciClone To Present At Boston Biotech NY/NJ CEO Conference On November 12th
2. AbbVie to Present at Credit Suisse 24th Annual Healthcare Conference
3. Data Supporting Delcaths CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress
4. Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
5. Douglas C. Wu, M.D., Ph.D., Presents The New Picoway Laser At The Aesthetics Academy
6. Perrigo Comments On Mylans Presentation
7. Warner Chilcott to Pay $125 Million to Resolve Kickback Allegations; Seeger Weiss LLP Represented Relators in Historic Healthcare Fraud Whistleblower Lawsuit
8. AMRI to Present at Credit Suisse Healthcare Conference
9. Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrologys Kidney Week Meeting 2015
10. 2015 Coagulation Testing Market - Presents Analyses of Major Manufacturers of Coagulation Products in Terms of their Sales, Market Shares and Product Portfolios
11. Henry Schein to Present at Two Investor Conferences in November
Post Your Comments:
(Date:8/19/2019)... ... August 19, 2019 , ... Transformations ... Annual National Sports Summit, August 25-26 at the Hyatt Place in Delray Beach, ... all major professional sports programs to discuss progress made over the last year ...
(Date:8/19/2019)... ... , ... Physician Partners of America Pain Relief Group is ... starting Monday, Sep. 2nd. , Dr. Spiro Khoury is board certified in Anesthesiology ... management. , Dr. Khoury attended the American University of the Caribbean School of ...
(Date:8/16/2019)... ... August 16, 2019 , ... A new medical device for ... that both corrects the curve and maintains flexibility in the spine. , The ... by medical staff of Shriners Hospitals for Children® — Philadelphia. It is the ...
Breaking Medicine Technology:
(Date:8/16/2019)... PARK, N.Y. (PRWEB) , ... August 16, 2019 ... ... fabricated, and donated a custom handcrafted, one-of-a-kind children’s aircraft to Ronald McDonald House ... was designed to give children residents undergoing medical treatments and their family members ...
(Date:8/16/2019)... ... 2019 , ... Dr. Demetri Arnaoutakis, a board-certified hair restoration ... , The Haute Beauty Network, well known for its exclusive and luxurious lifestyle ... expert and our newest addition to the Haute Beauty members-only network. , Haute ...
(Date:8/15/2019)... ... August 15, 2019 , ... The ASCP Foundation has ... directly affected by the closure of Hahnemann University Hospital in Philadelphia, which is ... the ASCP Foundation will be making hardship grants of up to $2,500 per ...
(Date:8/15/2019)... ... August 15, 2019 , ... Jon O'Brien, ... for family planning clinics to provide written assurance that they will comply with ... to the Global Gag Rule, the new policy restricts providers and clinics that ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
Breaking Medicine News(10 mins):